Page 61 - revista Ingeniantes 321 Interactivo

Revista Ingeniantes 2016 Año 3 No. 2 Vol. 1

REFERENCIAS factor for cutaneous melanoma. JAMA: The Jour-
[1] American Cancer Society. Cancer Facts and nal of the American Medical Association 1997;
Figures 2011 . Atlanta, GA: American Cancer So- 277(18):1439–1444. [PubMed Abstract]
ciety. Retrieved July 25, 2011. [14] Roberto Collado-Borrell, V. E.-V.-S.-G.-
[2] Cyr PR. Atypical moles. American Family Phy- A.-S. (12 de Octubre de 2015). Smartphone appli-
sician 2008; 78(6):735–740. [PubMed Abstract] cations for cancer patients; what we know about
[3] Friedman RJ, Farber MJ, Warycha MA, et al. them? Farmacia Hospitalaria, 25-35
The “dysplastic” nevus. Clinics in Dermatolo- [15] Eide, M. (2006). Epidemiología del cáncer de
gy2009; 27(1):103–115. [PubMed Abstract] piel. Cáncer De Piel, 47-60. doi:10.1016/b978-
[4] Goodson AG, Grossman D. Strategies for ear- 84-8174-875-8.50004-4
ly melanoma detection: Approaches to the patient [16] F., J. L., P., J. A., N., S. J., & C., D. C. (2010).
with nevi. J Am Acad Dermatol. 2009;60:719-735. Actualizaciones en melanoma maligno cutáneo.
[5] Goodson AG, Grossman D. Strategies for ear- Cuadernos De Cirugía, 24(1), 47-56. doi:10.4206/
ly melanoma detection: approaches to the pa- cuad.cir.2010.v24n1-08
tient with nevi. Journal of the American Academy [17] González, S. (2006). Microscopio con fo-
of Dermatology 2009; 60(5):719–738. [PubMed cal y cáncer de piel. Cáncer De Piel, 457-465.
Abstract] doi:10.1016/b978-84-8174-875-8.50037-8

[6] Hodi FS, O’Day SJ, McDermott DF, et al. Im- [18] Institutos Nacionales de la Salud de EE. UU. .
proved survival with ipilimumab in patients with (01 de Enero de 2012). INC Institutos Nacionales
metastatic melanoma. N Eng J Med. 2010;363:711- del Cáncer. Recuperado el 23 de Septiembre de
723. 2016, de Institutos Nacionales del Cáncer.
[7] Howlader N, Noone AM, Krapcho M, et al. (eds). https://www.cancer.gov/espanol/tipos/piel
SEER Cancer Statistics Review, 1975–2008.Be- [19] Pantoja Benavides, J. F., & Giraldo Ramos,
thesda, MD: National Cancer Institute. Based on F.N. (7 de 2010). Segmentación de imágenes uti-
November 2010 SEER data submission. Posted to lizando campos aleatorios de Markov. Universi-
the SEER Web site, 2011. Retrieved July 25, 2011. dad Distrital Francisco José de Caldas.

[8] Lange JR, Fecher LA, Sharfman WH, et al. [20] Cardacci, D. G. (2008). Algoritmos para la
Melanoma. In: Abeloff MD, Armitage JO, Nierder- interpretación y tratamiento de imágenes. Elec-
huber JE, Kastan MB, McKenna WG, eds. Abelo- trónico, Faculta de Tecnología Informática.
ff’s Clinical Oncology. 4th ed. Philadelphia, Pa:
Churchill Livingstone; 2008:chap 73.

[9] National Comprehensive Cancer Network.
NCCN Medical Practice Guidelines and Oncolo-
gy: Melanoma. V.4.2011.

[10] Rigel DS, Russak J, Friedman R. The evo-
lution of melanoma diagnosis: 25 years beyond
the ABCDs. CA: A Cancer Journal for Clinicians
2010; 60(5):301–316. [PubMed Abstract]

[11] Titus-Ernstoff L, Ding J, Perry AE, et al.
Factors associated with atypical moles in New
Hampshire, USA. Acta Dermato Venereologica
2007; 87(1):43–48. [PubMed Abstract]

[12] Tucker MA. Melanoma epidemiology. Hema-
tology/Oncology Clinics of North America 2009;
23(3):383–395. [PubMed Abstract]

[13] Tucker MA, Halpern A, Holly EA, et al. Cli-
nically recognized dysplastic nevi: a central risk

57